- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CD79B/ AGM6/ B29 monoclonal antibody
Anti-CD79B/ AGM6/ B29 antibody for FACS & in-vivo assay
Go to CD79B/CD79B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T08306-Ab-1/ GM-Tg-hg-T08306-Ab-2 | Anti-Human CD79B monoclonal antibody | Human |
| GM-Tg-rg-T08306-Ab-1/ GM-Tg-rg-T08306-Ab-2 | Anti-Rat CD79B monoclonal antibody | Rat |
| GM-Tg-mg-T08306-Ab-1/ GM-Tg-mg-T08306-Ab-2 | Anti-Mouse CD79B monoclonal antibody | Mouse |
| GM-Tg-cynog-T08306-Ab-1/ GM-Tg-cynog-T08306-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD79B monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T08306-Ab-1/ GM-Tg-felg-T08306-Ab-2 | Anti-Feline CD79B monoclonal antibody | Feline |
| GM-Tg-cang-T08306-Ab-1/ GM-Tg-cang-T08306-Ab-2 | Anti-Canine CD79B monoclonal antibody | Canine |
| GM-Tg-bovg-T08306-Ab-1/ GM-Tg-bovg-T08306-Ab-2 | Anti-Bovine CD79B monoclonal antibody | Bovine |
| GM-Tg-equg-T08306-Ab-1/ GM-Tg-equg-T08306-Ab-2 | Anti-Equine CD79B monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T08306-Ab-1/ GM-Tg-hg-T08306-Ab-2; GM-Tg-rg-T08306-Ab-1/ GM-Tg-rg-T08306-Ab-2; GM-Tg-mg-T08306-Ab-1/ GM-Tg-mg-T08306-Ab-2; GM-Tg-cynog-T08306-Ab-1/ GM-Tg-cynog-T08306-Ab-2; GM-Tg-felg-T08306-Ab-1/ GM-Tg-felg-T08306-Ab-2; GM-Tg-cang-T08306-Ab-1/ GM-Tg-cang-T08306-Ab-2; GM-Tg-bovg-T08306-Ab-1/ GM-Tg-bovg-T08306-Ab-2; GM-Tg-equg-T08306-Ab-1/ GM-Tg-equg-T08306-Ab-2 |
| Products Name | Anti-CD79B monoclonal antibody |
| Format | mab |
| Target Name | CD79B |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CD79B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-INN-962 | Pre-Made Polatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody Drug Conjugate |
| Biosimilar | GMP-Bios-INN-862 | Pre-Made Iladatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody Drug Conjugate |
| Biosimilar | GMP-Bios-ab-264 | Pre-Made Iladatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody |
| Biosimilar | GMP-Bios-ab-449 | Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody |
| Target Antigen | Products Developing | Multi-species CD79B/ AGM6/ B29 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLP000751 | human CD79B Lentivirus particle |
| ORF Viral Vector | pGMLP000751 | human CD79B Lentivirus plasmid |
Target information
| Target ID | GM-T08306 |
| Target Name | CD79B |
| Gene ID | 974,15985,171055,718218,609449,101098098,509801,100064460 |
| Gene Symbol and Synonyms | AGM6,B29,CD79B,Ig-beta,IGB,Igbeta |
| Uniprot Accession | P40259 |
| Uniprot Entry Name | CD79B_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | Cancer |
| Gene Ensembl | ENSG00000007312 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CD79B, gene name: CD79B, also named as AGM6, B29, IGB. The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
